ArticleEye (London, England)2020
Recent trends in vision impairment certifications in England and Wales.
Article in Eye (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 70 citations in OpenAlex.
- Visual impairment certifications in England over 16 years: annual numbers attributable to age-related macular degeneration, glaucoma, diabetes and hereditary eye disease.Eye (London, England) · 2026Article
- Exploring variations in Certificate of Vision Impairment (CVI) with geographical locations, deprivation indices, density of optometry practices and number of older people living in Mid and South Essex: an analysis of publicly available data.Eye (London, England) · 2026Article
- Photopharmacology: A new paradigm for vision restoration.Clinical and translational medicine · 2026Article
- Intravitreal photoswitch therapy in advanced retinitis pigmentosa: a phase 1 open-label trial.Nature medicine · 2026Article
- Inherited retinal disorders in Scotland: A 5 year assessment.Eye (London, England) · 2026Article
- Historical change in midlife trajectories of self-reported sensory functioning across 16 nations.The Gerontologist · 2026Article
- Global burden and cross-country inequalities of age-related eye diseases from 1990 to 2021: a comprehensive analysis of temporal trends and socioeconomic disparities.Eye and vision (London, England) · 2026Article
- Review
- Using Steady-State Visual Evoked Potentials to Characterize Wide-Ranging Retinopathy Linked toComputational and structural biotechnology journal · 2026Article
- Trends in paediatric visual impairment in England and Wales: a retrospective study (2009-2022).Eye (London, England) · 2025Article
- Some current issues in certification of vision impairment.Eye (London, England) · 2025Article
- Factors associated with achieving various visual acuity outcomes during loading doses of aflibercept 2 mg for treatment naïve exudative age-related macular degeneration: PRECISE Study Report 7.Eye (London, England) · 2025Article
- Associations between certification of visual impairment and socioeconomic deprivation: a study using data from the regional Northern Ireland sight impairment certification database.BMJ open ophthalmology · 2025Article
- Clinical and genetic landscape of IRD in Portugal: pooled data from the nationwide IRD-PT registry.NPJ genomic medicine · 2025Article
- Comparison of CRISPR-Cas13b RNA base editing approaches for USH2A-associated inherited retinal degeneration.Communications biology · 2025Article
- Global certification of visual impairment registries: A scoping review.Acta ophthalmologica · 2025Article
- Post COVID glaucoma service redesign utilising electronic patient triage and community optometry clinics (Fife, Scotland 2020-2022).BMC ophthalmology · 2025Article
- Article
- Optometrist-delivered selective laser trabeculoplasty in the HES - a training protocol and early service evaluation.Eye (London, England) · 2024Article
- Real-world experience of using stereotactic radiotherapy combined with anti-vascular endothelial growth factor to treat neovascular AMD.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Certificate of Visual Impairment (CVI) provides essential data for preventable sight loss indicators as part of the Public Health Outcomes Framework (PHOF) published annually by the Department of Health. Trends in CVI certification rates can provide information on the effectiveness of current services and treatments and may be used to guide allocation of resources, and is the only such indicator within ophthalmology. This study aimed to compare recent trends in new vision impairment certifications in 2017/18 against prior baseline data in England and document trends in new certifications in Wales.
methodsPHOF data from 2010/11 and 2017/18 were examined with respect to preventable sight loss indicators: age-related macular degeneration (AMD) (Indicator E12a), glaucoma (Indicator E12b), diabetic eye disease (Indicator E12c) as well as the total numbers of certifications (Indicator E12d).
resultsIn 2017/18, the rate of new CVI certifications was 41 per 100,000 population which has reduced from 43/100,000 in 2010/11 in England. Certifications for AMD reduced from 132/100,000 in 2010/11 to 107/100,000 in 2017-18. Certifications for glaucoma have remained stable at 13/100,000 in 2017/8. Certifications for diabetic eye disease have declined from 4/100,000 in 2010/11 to 3/ 100,000 in 2017/18. The number of vision impaired individuals that each Clinical Commissioning Group (CCG) has to support varies from 8 to 82 per 100,000 population.
conclusionsThere has been a significant decrease in the rate of all CVI certifications particularly from AMD and diabetic retinopathy. However, maintaining this will require changes in the way care is delivered as the elderly population, which is at greatest risk of preventable sight loss, is projected to increase by 50% over the next 20 years. Inherited retinal diseases are now the leading cause of sight loss in the working age population. CVI data demonstrate the need for CCGs to tailor their investment in ophthalmic services to the needs of their specific patient populations. It is important that all ophthalmologists continue to provide accurate CVI data in order to help support the future equitable allocation of adequate resources to reduce avoidable vision loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.